These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20630459)

  • 1. Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.
    Tsimikas S; Leibundgut G
    JACC Cardiovasc Interv; 2010 Jun; 3(6):657-9. PubMed ID: 20630459
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet function analysis: at the edge of meaning.
    Oestreich JH; Smyth SS; Campbell CL
    Thromb Haemost; 2009 Feb; 101(2):217-9. PubMed ID: 19190799
    [No Abstract]   [Full Text] [Related]  

  • 4. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
    Cuisset T; Frere C; Poyet R; Quilici J; Gaborit B; Bali L; Brissy O; Lambert M; Morange PE; Alessi MC; Bonnet JL
    Arch Cardiovasc Dis; 2010 Jan; 103(1):39-45. PubMed ID: 20142119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
    Faxon DP
    Nat Rev Cardiol; 2010 Mar; 7(3):124-5. PubMed ID: 20179718
    [No Abstract]   [Full Text] [Related]  

  • 8. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
    JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
    Blindt R; Stellbrink K; de Taeye A; Müller R; Kiefer P; Yagmur E; Weber C; Kelm M; Hoffmann R
    Thromb Haemost; 2007 Dec; 98(6):1329-34. PubMed ID: 18064332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
    Siller-Matula JM; Christ G; Lang IM; Delle-Karth G; Huber K; Jilma B
    J Thromb Haemost; 2010 Feb; 8(2):351-9. PubMed ID: 19943879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O
    Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
    Mangiacapra F; De Bruyne B; Muller O; Trana C; Ntalianis A; Bartunek J; Heyndrickx G; Di Sciascio G; Wijns W; Barbato E
    JACC Cardiovasc Interv; 2010 Jan; 3(1):35-40. PubMed ID: 20129566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
    Morel O; Bernhard N; Desprez D; Grunebaum L; Freyssinet JM; Toti F; Bareiss P
    Thromb Haemost; 2008 Feb; 99(2):448-51. PubMed ID: 18278200
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of chronic kidney disease on platelet P2Y
    Engwenyu LR; Franchi F; Rollini F; Cho JR; DeGroat C; Bhatti M; Alobaidi Z; Ferrante E; Jakubowski JA; Sugidachi A; Zenni M; Bass TA; Angiolillo DJ
    Thromb Haemost; 2017 Jan; 117(1):201-203. PubMed ID: 27786340
    [No Abstract]   [Full Text] [Related]  

  • 17. Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.
    Cayla G; Macia JC; Roubille F; Rabesendratana H; Piot C; Schved JF; Leclercq F
    Circ J; 2008 Dec; 72(12):2098-100. PubMed ID: 18854615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity.
    Barragan P; Paganelli F; Camoin-Jau L; Bourguet N; Boulay-Moine D; Moulard M; Bonello L
    Thromb Haemost; 2010 Aug; 104(2):410-1. PubMed ID: 20589315
    [No Abstract]   [Full Text] [Related]  

  • 19. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
    Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
    Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.